UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 18, 2007
Calypte Biomedical Corporation
(Exact name of Company as specified in its charter)
Delaware | 000-20985 | 06-1226727 |
(State or Other Jurisdiction) | (Commission File Number) | (I.R.S. Employer Identification) |
of Incorporation) | | |
16290 S.W. Upper Boones Ferry Road, Portland, Oregon 97224
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (503) 726-2227
N/A
(Former name or former address, if changed since last report)
| o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c)) |
Item 7.01 - Regulation FD Disclosure.
On September 18, 2007, Calypte Biomedical Corporation (the “Company”) held a webcast conference call with analysts and investors, during which Roger I. Gale, the Company’s Chairman and Chief Executive Officer, and Ronald W. Mink Ph.D., the Company’s Chief Scientific Officer, discussed the approval of the Company’s Aware® HIV-1/2 OMT oral fluid rapid test by the U.S. Agency for International Development (“USAID”) and its inclusion on the USAID waiver list and provided updates on the Company’s operations. A copy of the prepared remarks of Messrs. Gale and Mink is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | | Description |
| 99.1 | | Prepared Remarks of Roger I. Gale and Ronald W. Mink for Calypte Biomedical Corporation Analyst/Investor Conference Call held on September 18, 2007. |
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 18, 2007 | | |
| | | |
| | Calypte Biomedical Corporation |
|
|
|
| | By: | /s/ Jerrold D. Dotson |
| |
Jerrold D. Dotson |
| | Vice President - Finance and Administration |
